Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer

doi:10.4240/wjgs.v16.i5.1395

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (589)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

364

Figures (1-3)

Tables (1-3)

Sum=503

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=63

May 27, 2024 (publication date) through Jul 5, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Surg. May 27, 2024; 16(5): 1395-1406
Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1395

Table 1 Histological and clinical characteristics of colorectal cancer patients, n (%)

Variable	Value
Gender
Male	112 (54.6)
Female	93 (45.4)
Age (yr)
≥ 60	106 (51.7)
< 60	99 (48.3)
Primary site
Colon	140 (68.3)
Rectum	65 (31.7)
Tumor type
Exophytic type	151 (73.7)
Ulcerative type	54 (26.3)
LVI
Present	64 (31.2)
Absent	141 (68.8)
PNI
Present	58 (28.3)
Absent	147 (71.7)
EMVI
Present	31 (15.1)
Absent	174 (84.9)
LNM
Present	89 (43.4)
Absent	116 (56.6)
PDC
Present	152 (74.1)
Absent	53 (25.9)
TB
BD1	117 (57.1)
BD2	40 (19.5)
BD3	48 (23.4)
Histologic differentiation
P/D or mucinous	53 (25.9)
M/D	142 (69.3)
W/D	10 (4.9)
Tumor stage
I	34 (16.6)
II	72 (35.1)
III	80 (39.0)
IV	19 (9.3)
c-MET immunohistochemistry
0	3 (1.4)
1+	51 (24.9)
2+	112 (54.7)
3+	39 (19.0)
MET FISH (Cappuzzo criteria)
MET GCN ≥ 5	28 (14.4)
MET GCN < 5	167 (85.6)
MET FISH (PathVysion criteria)
MET/CEP7 ≥ 2	0 (0.0)
MET/CEP7 < 2	195 (100.0)

EMVI: Extramural venous invasion; GCN: Gene copy number; LNM: Lymph node metastasis; LVI: Lymphovascular invasion; M/D: Moderately differentiated; P/D: Poorly differentiated; PDC: Poorly differentiated clusters; PNI: Perineural invasion; TB: Tumor budding; W/D: Well differentiated.

Table 2 Correlations between polysomy-caused mesenchymal-epithelial transition factor amplification and clinicopathological characteristics of colorectal cancer patients, n (%)

Characteristic	MET FISH			P value
Characteristic	*Positive MET* GCN ≥ 5 (n = 28)**	*Negative MET* GCN < 5 (n = 167)**	Total (n = 195)	P value
Gender				0.975
Male	15 (53.60)	90 (53.90)	105 (53.80)
Female	13 (12.90)	77 (46.21)	90 (46.20)
Age (yr)				0.085
≥ 60	19 (67.90)	84 (50.30)	103 (52.80)
< 60	9 (32.10)	83 (49.70)	92 (47.20)
Primary site				0.077
Colon	23 (82.10)	109 (65.30)	132 (67.70)
Rectum	5 (17.90)	58 (34.70)	63 (32.30)
Tumor type				0.187
Exophytic type	18 (64.30)	127 (76.00)	145 (74.40)
Ulcerative type	10 (35.70)	40 (24.00)	50 (25.60)
LVI				0.261
Present	11 (39.30)	48 (28.70)	59 (30.30)
Absent	17 (60.70)	119 (71.30)	136 (69.70)
PNI				0.377
Present	10 (35.70)	46 (27.50)	56 (28.70)
Absent	18 (64.30)	121 (72.50)	139 (71.30)
EMVI				0.500
Present	6 (21.40)	24 (14.40)	30 (15.40)
Absent	22 (78.60)	143 (85.60)	165 (84.60)
LNM				< 0.001
Present	21 (75.00)	60 (35.90)	81 (41.50)
Absent	7 (25.00)	107 (64.10)	114 (58.50)
PDC				0.153
Present	24 (85.70)	122 (73.10)	146 (74.90)
Absent	4 (14.30)	45 (26.90)	49 (25.10)
TB				0.020
BD1	10 (35.70)	99 (59.30)	109 (55.9)
BD2/3	18 (64.30)	68 (40.70)	86 (44.10)
Histologic differentiation				0.933
P/D or mucinous	7 (25.00)	43 (25.70)	50 (25.60)
W/D or M/D	21 (75.00)	124 (74.30)	145 (74.40)

MET: Mesenchymal-epithelial transition factor; EMVI: Extramural venous invasion; GCN: Gene copy number; LNM: Lymph node Metastasis; LVI: Lymphovascular invasion; M/D: Moderately differentiated; P/D: Poorly differentiated; PDC: Poorly differentiated clusters; PNI: Perineural invasion; TB: Tumor budding; W/D: Well differentiated.

Table 3 Correlations between c-mesenchymal-epithelial transition factor protein expression and clinicopathological characteristics of colorectal cancer patients, n (%)

Characteristic	C-MET IHC				P value
Characteristic	0/1+ (n = 54)	2+ (n = 112)	3+ (n = 39)	Total (n = 205)	P value
Gender					0.525
Male	33 (61.1)	58 (51.8)	21 (53.8)	112 (54.6)
Female	21 (38.9)	54 (48.2)	18 (46.2)	93 (45.4)
Age (yr)					0.138
≥ 60	33 (61.1)	51 (45.4)	22 (56.4)	106 (51.7)
< 60	21 (38.9)	61 (54.5)	17 (43.6)	99 (48.3)
Primary site					0.805
Colon	38 (70.4)	77 (68.8)	25 (64.1)	140 (68.3)
Rectum	16 (29.6)	35 (31.3)	14 (35.9)	65 (31.7)
Tumor type					0.656
Exophytic type	39 (72.2)	81 (72.3)	31 (79.5)	151 (73.7)
Ulcerative type	15 (27.8)	31 (27.7)	8 (20.5)	54 (26.3)
LVI					0.941
Present	17 (31.5)	34 (30.4)	13 (33.3)	64 (31.2)
Absent	37 (68.5)	78 (69.6)	26 (66.7)	141 (68.8)
PNI					0.897
Present	15 (27.8)	33 (29.5)	10 (25.6)	58 (28.3)
Absent	39 (72.2)	79 (70.5)	29 (74.4)	147 (71.7)
EMVI					0.252
Present	5 (9.3)	21 (18.8)	5 (12.8)	31 (15.1)
Absent	49 (90.7)	91 (81.3)	34 (87.2)	174 (84.9)
LNM					0.002
Present	18 (33.0)¹	56 (50.0)¹	25 (64.1)¹	89 (43.4)
Absent	36 (67.0)¹	56 (50.0)¹	14 (35.9)¹	116 (56.6)
PDC					0.188
Present	35 (64.8)	87 (77.7)	30 (76.9)	152 (74.1)
Absent	19 (35.2)	25 (22.3)	9 (23.1)	53 (25.9)
TB					0.148
BD1	34 (63.0)	66 (58.9)	17 (43.6)	117 (57.1)
BD2/3	20 (37.0)	46 (41.1)	22 (56.4)	88 (42.9)
Histologic differentiation					0.541
P/D or mucinous	17 (31.5)	27 (24.1)	9 (23.1)	53 (25.9)
W/D or M/D	37 (68.5)	85 (75.9)	30 (76.9)	152 (74.1)

¹Each superscript letter denotes a subset of MET mesenchymal-epithelial transition factor immunohistochemistry categories whose column proportions do not differ significantly from each other at the 0.05 level.

MET: Mesenchymal-epithelial transition factor; EMVI: Extramural venous invasion; LNM: Lymph node metastasis; LVI: Lymphovascular invasion; M/D: Moderately differentiated; P/D: Poorly differentiated; PDC: Poorly differentiated clusters; PNI: Perineural invasion; TB: Tumor budding; W/D: Well differentiated.

Citation: Yu QX, Fu PY, Zhang C, Li L, Huang WT. Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer. World J Gastrointest Surg 2024; 16(5): 1395-1406
URL: https://www.wjgnet.com/1948-9366/full/v16/i5/1395.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i5.1395